gynecologic cancer intergroup cervix cancer research network cantu surgery.pdf18 (50%) 5...

22
Gynecologic Cancer InterGroup Cervix Cancer Research Network Role of Surgery in Cervical Cancer David Cantú MD PhD Cervix Cancer Education Symposium, January 2017, Mexico

Upload: others

Post on 02-Dec-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Role of Surgery in Cervical Cancer

David Cantú MD PhD

Cervix Cancer Education Symposium, January 2017, Mexico

Page 2: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Is it still an Issue to

be explored?

?

Page 3: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)
Page 4: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Continues to be the cornerstone of

treatment in early stages

Page 5: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 6: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Tumor Size

• Desire for fertility preservation

• Neoadjuvant chemotherapy

• Sentinel lymph node

Page 7: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 8: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Minimally Invasive Procedures

Page 9: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 10: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Facilities

• Training

• Preferences

• COSTS!!!!

Page 11: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Locally Advanced Disease

Page 12: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 13: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 14: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 15: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Page 16: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Recurrent Disease

Page 17: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Objetivo :

Definir selección de px para EP en CaCu recurrente , El grado óptimo de la cirugía en términos de morbilidad y mortalidad.

European Journal of Surgical Oncology (2015), doi: 10.1016/j.ejso.2015.03.235.

Material y Metodos:

•Revisión de la literatura,

•Artículos publicados en los últimos 25 años:

•Exenteración pélvica,

•Cáncer cervical recurrente,

•Tratamiento del cáncer cervical,

•Radioterapia y cáncer de cuello uterino.

Page 18: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

European Journal of Surgical Oncology (2015), doi: 10.1016/j.ejso.2015.03.235.

• .

Descartar la presencia de mets.

• Resección completa del tumor con márgenes quirúrgicos no involucrados y es un fuerte factor pronóstico de supervivencia postoperatoria.

La cirugía curativa requiere

• 40% de EP fueron abortados IOp debido a una enfermedad no resecable.

1989

CaCU recurrente a Distancia:

Para-aórtica 81%

Supraclavicular 7%

Ganglios linfáticos pulmonares 21%

Page 19: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

• Difícil comparar los resultados, – Heterogeneidad respecto al tipo de procedimiento y

el tipo de cáncer que se está investigando (cervical, endometrial, de ovario o vulvar).

• Rara vez se centran únicamente en CaCU y aún más raramente en la recidiva.

• No explican cómo o por qué se eligió un procedimiento dado.

• Márgenes quirúrgicos negativos es un importante factor pronóstico, potencialmente modificable.

European Journal of Surgical Oncology (2015), doi: 10.1016/j.ejso.2015.03.235.

Page 20: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

AutorR Complicacione

s tempranas

Tipo Complicacione

s tardías

tipo Muertes

Berek NR NR NR 17 fitula gatrointetinal 3 (4%)

Goldberg NR NR NR NR 1 (0.9%)

Maggioni 48 (44.8%) NR 52 (48,5%) NR 0

Benn 27 (50%) 10 cardioresp, 6 ileo, 1

obstruction ureteral

33 (61%) 15 ileo, 11 ureteral, 15

hernias

0

McLean NR 15 infections, 8 abscesses, 6

sepsis

NR NR 1 (2%)

Vergote 21 (58%) 2 pelvic abscesses, 14

leaking stomas and

sepsis

18 (50%) 5 pielonefritis

14 fistulas

1 (2%)

Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic

infections

48 (44.8%) 8 fistulas, 9 occlusions, 16

Obstruction urinaria

13 (12%)

Yoo 10 (16 %) 4 skin infections, 1 ileus

5 fistulas, 3 wound

dehiscences

22 (36%) 10 fistulas (7

enterocutaneea,

2 rectovaginal, 1

Ureteroenteric)

0

Schmidt 143 (51%) 42 rectovaginal fistulas, 20

pelvic

abscesses, 10 pulmonary

emboli

NR NR 14 (5%)

Tanaka 10 ( 83%) 5 ileus, 3 leaking

gastrointenstinal

anastomoses

NR NR 0

Chiantera 48 8 21.3%) 23 sepsis, 15

cardiorespiratory, 39 wound

dehiscences, 22 urinary, 29

gastrointenstinal

NR NR 7 (3%)

European Journal of Surgical Oncology (2015), doi: 10.1016/j.ejso.2015.03.235.

Page 21: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

• Palliative Procedures

– Ileal Conduit

– Colostomy

– Other diversions

– Other Procedures

Page 22: Gynecologic Cancer InterGroup Cervix Cancer Research Network Cantu SURGERY.pdf18 (50%) 5 pielonefritis 14 fistulas 1 (2%) Baiocch 57 ( 53.3%) 13 fistulas, 17 pelvic infections 48 (44.8%)

Gynecologic Cancer InterGroup

Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2017, Mexico

Is it still an Issue to

be explored?

?